PARKINSON's DISEASE SYMPTOMATIC TREATMENT MARKETS
Executive Summary
PARKINSON's DISEASE SYMPTOMATIC TREATMENT MARKETS are attractive targets for central nervous system research, Wilkerson Group VP Robert Easton indicated at an April 17 symposium co-sponsored by Frost & Sullivan and the National Pharmaceutical Council. Maintaining that a cure for the disease could generate $4-$5 bil. annually, Easton pointed out that drugs for the symptoms of the disease also offer attractive product development opportunities: "A drug that fixed the freezing problem [where a patient cannot move his feet] or the very specific urinary incontinence problem of Parkinson's patients would be worth a couple of hundred million dollars per year," he said. Parkinson's is among numerous diseases or conditions in the central nervous system area where there is either no therapy or the existing therapy is "not very good," Easton said. The unmet need, he suggested, makes that area a fertile research area. Easton outlined 14 CNS-related disorders with a total theoretical annual U.S. market potential (at manufacturer level) of roughly $16 bil., ranging from ALS (Lou Gehrig's disease) at $25 mil. to Alzheimer's disease at $6 bil. Among the other conditions with estimated market potentials above $1 bil. per year are eating disorders, mood disorders, Parkinson's, sleep dysfunction, anxiety disorders, and stroke. The market potentials, Easton noted, are based on "a very conservative pricing model." For example, he said, the $25 mil. figure for an ALS therapy "is based on what I'd call 'namby pamby' pharmaceutical pricing," charging $1,500/year/patient. "If you really price to value, which I urge and recommend all of you to do, and which I think Wellcome has shown us to do [with AZT] and Genentech [with TPA], instead of being a $25 mil. drug growing to $90 mil. [in 10 years], it would be a $80 mil. drug growing to about a quarter of a billion dollars." The Wilkerson Group exec identified several products with an unmet therapeutic need and promising ongoing research, yet relatively low competition, including: excitatory amino acids and opioid peptides for stroke; neuropeptides for Alzheimer's; and neuropeptides for eating disorders. Other promising areas with slightly greater competitive intensity include excitatory amino acids for epilepsy and Alzheimer's and serotonin for eating disorders. The Wilkerson Group recently issued a report entitled The Challenge of Neuroscience: Clinical Perspectives and Commercial Prospects. Chart omitted.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: